Cutting edge:: NKG2D is a costimulatory receptor for human naive CD8+ T cells

被引:150
|
作者
Maasho, K [1 ]
Opoku-Anane, J [1 ]
Marusina, AI [1 ]
Coligan, JE [1 ]
Borrego, F [1 ]
机构
[1] NIAID, Receptor Cell Biol Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA
来源
JOURNAL OF IMMUNOLOGY | 2005年 / 174卷 / 08期
关键词
D O I
10.4049/jimmunol.174.8.4480
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In humans, all alpha beta CD8(+) T cells express NKG2D, but in mouse, it is only expressed by activated and memory CD8(+) Tcells. We purified human naive CD8+ Tcells to show that NKG2D serves as a costimulatory receptor for TCR induced Ca2+ mobilization and proliferation. The resulting effector cells are skewed toward a type 1 phenotype and produce high levels of IFN-gamma and TNF-alpha NKG2D ligands, MHC class I chain-related (MIC)A, MICB, and UL16-binding proteins are expressed on the proliferating cells and NKG2D is down-regulated, The addition of the homeostatic cytokines IL-7 and IL-15 to the culture medium not only enhances proliferation but also counteracts the down-regulation of NKG2D, more so than the addition of IL-2. These results indicate that NKG2D can regulate the priming of human naive CD8+ Tcells, which may provide an alternative mechanism for potentiating and channeling the immune response.
引用
收藏
页码:4480 / 4484
页数:5
相关论文
共 50 条
  • [1] Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy
    Kushal Prajapati
    Cynthia Perez
    Lourdes Beatriz Plaza Rojas
    Brianna Burke
    Jose A Guevara-Patino
    Cellular & Molecular Immunology, 2018, 15 : 470 - 479
  • [2] Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy
    Prajapati, Kushal
    Perez, Cynthia
    Rojas, Lourdes Beatriz Plaza
    Burke, Brianna
    Guevara-Patino, Jose A.
    CELLULAR & MOLECULAR IMMUNOLOGY, 2018, 15 (05) : 470 - 479
  • [3] NKG2D co-stimulation of human naive CD8+T cells
    Borrego, F
    Maasho, K
    Opoku-Anane, J
    Marusina, AI
    Valas, R
    Coligan, JE
    FASEB JOURNAL, 2005, 19 (04): : A907 - A907
  • [4] Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells
    Cerboni, Cristina
    Ardolino, Michele
    Santoni, Angela
    Zingoni, Alessandra
    BLOOD, 2009, 113 (13) : 2955 - 2964
  • [5] Modulation of NKG2D Expression in Human CD8+ T Cells Corresponding with Tuberculosis Drug Cure
    Hassan, Syeda S.
    Cho, Jang-Eun
    Akram, Muhammad
    Fielding, Katherine L.
    Dockrell, Hazel M.
    Cliff, Jacqueline M.
    PLOS ONE, 2013, 8 (07):
  • [6] Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
    Verneris, MR
    Karami, M
    Baker, J
    Jayaswal, A
    Negrin, RS
    BLOOD, 2004, 103 (08) : 3065 - 3072
  • [7] TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells glioma patients
    Crane, Courtney A.
    Han, Seunggu J.
    Barry, Jeffery J.
    Ahn, Brian J.
    Lanier, Lewis L.
    Parsa, Andrew T.
    NEURO-ONCOLOGY, 2010, 12 (01) : 7 - 13
  • [8] MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
    Peeters, Marlies J. W.
    Dulkeviciute, Donata
    Draghi, Arianna
    Ritter, Cathrin
    Rahbech, Anne
    Skadborg, Signe K.
    Seremet, Tina
    Simoes, Ana Micaela Carnaz
    Martinenaite, Evelina
    Halldorsdottir, Holmfridur R.
    Andersen, Mads Hald
    Olofsson, Gitte Holmen
    Svane, Inge Marie
    Rasmussen, Lene Juel
    Met, Ozcan
    Becker, Juergen C.
    Donia, Marco
    Desler, Claus
    Straten, Per Thor
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (09) : 1472 - 1484
  • [9] NKG2D, An NK Cell Activating Receptor on CD8+ T Cells, Plays An Essential Role In Killing Myeloma Cells
    Talebian, Laleh
    Meehan, Kenneth
    Patey, Megan E.
    Fisher, Dawn A.
    Szczepiorkowski, Zbigniew
    Ernstoff, Marc
    Sentman, Charles
    BLOOD, 2010, 116 (21) : 866 - 866
  • [10] Soluble NKG2D ligands impair CD8+ T cell antitumor function dependent of NKG2D downregulation in neuroblastoma
    Zhang, Yi
    Luo, Feifei
    Dong, Kuiran
    ONCOLOGY LETTERS, 2023, 26 (01)